Evaluation of a High-Throughput Fluorescence Assay Method for hERG Potassium Channel Inhibition

The number of projects in drug development that fail in late phases because of cardiac side effects such as QT prolongation can impede drug discovery and development of projects. The molecular target responsible for QT prolongation by a wide range of pharmaceutical agents is the myocardial hERG potassium channel. It is therefore desirable to screen for compound interactions with the hERG channel at an early stage of drug development. Here, the authors report a cell-based fluorescence assay using membrane potential-sensitive fluorescent dyes and stably transfected hERG channels from CHO cells. The assay allows semiautomated screening of compounds for hERG activity on 384-well plates and is sufficiently rapid for testing a large number of compounds. The assay is robust as indicated by a Z′ factor larger than 0.6. The throughput is in the range of 10,000 data points per day, which is significantly higher than any other method presently available for hERG. The data obtained with the fluorescence assay were in qualitative agreement with those from patch-clamp electrophysiological analysis. There were no false-positive hits, and the rate of false-negative compounds is currently 12% but might be further reduced by testing compounds at higher concentration. Quantitative differences between fluorescence and electrophysiological methods may be due to the use- or voltage-dependentactivity of the antagonists.

[1]  M. Yamamoto,et al.  Acute canine model for drug-induced Torsades de Pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  B Attali,et al.  The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes , 1997, British journal of pharmacology.

[3]  D. Roden.  Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. , 1996, Circulation.

[4]  W. Giles,et al.  Repolarizing K+ currents in rabbit heart Purkinje cells , 1998, The Journal of physiology.

[5]  L. Satin,et al.  ATP-sensitive K+ channels in pancreatic beta-cells. Spare-channel hypothesis. , 1988, Diabetes.

[6]  F. Ponti,et al.  QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience , 2000, European Journal of Clinical Pharmacology.

[7]  C. January,et al.  Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole , 1999, Journal of cardiovascular electrophysiology.

[8]  J. Gras,et al.  Effects of H1 Antihistamines on Animal Models of QTc Prolongation , 1999, Drug safety.

[9]  M. Sanguinetti,et al.  Molecular biology of K(+) channels and their role in cardiac arrhythmias. , 2001, The American journal of medicine.

[10]  Christine Williams,et al.  Patch clamping by numbers. , 2004, Drug discovery today.

[11]  Ich Harmonised,et al.  INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE , 2006 .

[12]  R Lazzara,et al.  Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. , 1996, Circulation.

[13]  Andreas Sewing,et al.  High-Throughput Screening for Ion Channel Modulators , 2002, Journal of biomolecular screening.

[14]  A. Brown,et al.  A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG , 1997, FEBS letters.

[15]  T. Garyantes,et al.  Development and Evaluation of High Throughput Functional Assay Methods for hERG Potassium Channel , 2001, Journal of biomolecular screening.

[16]  A. Brown,et al.  Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. , 2001, Molecular pharmacology.

[17]  G. Gintant,et al.  The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis , 2001, Journal of cardiovascular pharmacology.

[18]  W. Rogers,et al.  Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. , 1989, The New England journal of medicine.

[19]  D. Rampe,et al.  High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. , 2000, European journal of pharmacology.

[20]  D. Escande,et al.  Gastrointestinal prokinetic drugs have different affinity for the human cardiac human ether-à-gogo K(+) channel. , 2001, The Journal of pharmacology and experimental therapeutics.

[21]  C. January,et al.  [3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. , 2001, European journal of pharmacology.

[22]  L. Opie,et al.  Sotalol , 2021, Reactions Weekly.

[23]  O. Pongs,et al.  Effects of fluoroquinolones on HERG currents. , 2000, European journal of pharmacology.

[24]  Hao Wang,et al.  Functional and pharmacological properties of canine ERG potassium channels. , 2003, American journal of physiology. Heart and circulatory physiology.

[25]  Rory Curtis,et al.  A Novel Membrane Potential-Sensitive Fluorescent Dye Improves Cell-Based Assays for Ion Channels , 2002, Journal of biomolecular screening.

[26]  Qiuming Gong,et al.  Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride. , 1997, American journal of physiology. Heart and circulatory physiology.

[27]  D. Epps,et al.  Characterization of the steady-state and dynamic fluorescence properties of the potential-sensitive dye bis-(1,3-dibutylbarbituric acid)trimethine oxonol (Dibac4(3)) in model systems and cells. , 1994, Chemistry and physics of lipids.

[28]  Jules C Hancox,et al.  Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. , 2002, Journal of pharmacological and toxicological methods.

[29]  M. Weir,et al.  The Cardiac Arrhythmia Suppression Trial Investigators: Preliminary Report: Effect of Encainide and Flecainide on Mortality in a Randomized Trial of Arrhythmia Suppression After Myocardial Infarction. , 1990 .

[30]  F. Lang,et al.  Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole , 1996, FEBS letters.

[31]  E. Green,et al.  A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome , 1995, Cell.

[32]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[33]  Rita R. Patel,et al.  A High-Throughput HERG Potassium Channel Function Assay: An Old Assay with a New Look , 2002, Drug development and industrial pharmacy.

[34]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[35]  P. Negulescu,et al.  Cell-based assays and instrumentation for screening ion-channel targets. , 1999, Drug discovery today.

[36]  O. Pongs,et al.  Screening lead compounds for QT interval prolongation. , 2001, Drug discovery today.

[37]  Sujatha M. Gopalakrishnan,et al.  Validation of FLIPR Membrane Potential Dye for High Throughput Screening of Potassium Channel Modulators , 2001, Journal of biomolecular screening.

[38]  C. January,et al.  Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. , 1999, Circulation research.

[39]  M. Sanguinetti,et al.  A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channel , 1995, Cell.

[40]  M. Emri,et al.  Flow cytometric determination of absolute membrane potential of cells. , 1995, Journal of photochemistry and photobiology. B, Biology.

[41]  E. Aliot,et al.  The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. , 1988, Progress in cardiovascular diseases.

[42]  Leslie S. Satin,et al.  ATP-Sensitive K+ Channels in Pancreatic β-Cells: Spare-Channel Hypothesis , 1988, Diabetes.